A GC DNA probe is a laboratory test that detects gonorrhea (and often chlamydia) by identifying the genetic material of the bacteria in a swab or urine sample. “GC” stands for gonococcus, the shorthand name for Neisseria gonorrhoeae, the bacterium that causes gonorrhea. The test works by using a synthetic strand of DNA that matches a specific sequence unique to the target bacteria. If that bacteria’s genetic material is present in your sample, the probe binds to it and produces a measurable signal, confirming infection.
How the Test Works
The core technology relies on a principle called hybridization. The lab uses a single-stranded DNA probe that is designed to be complementary to a section of the bacterium’s ribosomal RNA, a genetic sequence unique to that species. When your sample is processed, if the target bacteria is present, the probe locks onto the matching RNA like two puzzle pieces fitting together. The probe carries a chemical label that produces light (chemiluminescence) when binding occurs, and the lab instrument reads that light signal to determine whether the bacteria was found.
The most widely known version of this technology is the PACE 2 system, manufactured by Gen-Probe (now Hologic). It can test for gonorrhea alone or for both gonorrhea and chlamydia from the same sample. One important detail: the combined version of the test (PACE 2C) does not distinguish between the two infections. A positive result on a combined test needs to be followed up with organism-specific testing to confirm which infection you have.
What Samples Are Collected
For women, the test typically requires an endocervical swab, collected during a pelvic exam. For men, a urethral swab is the standard collection method. Some testing platforms also accept urine samples, though the DNA probe specifically tends to perform best with swab specimens rather than urine. The collection itself takes seconds and causes minimal discomfort, though urethral swabs in men can be briefly uncomfortable.
Results generally come back within about 3 working days, though turnaround time varies by lab.
Accuracy and Limitations
The DNA probe is highly specific, meaning that when it returns a positive result, the chance of a false positive is very low (specificity above 99%). However, its sensitivity, the ability to catch every true infection, is a known weakness. In a large multicenter study comparing the PACE 2 DNA probe to newer amplification-based tests, the probe’s sensitivity for chlamydia was around 61 to 78%, depending on the comparison standard used. That means it can miss roughly 1 in 4 to 1 in 3 infections.
False results can happen for several reasons. A false negative may occur if the bacterial load in the sample is too low for the probe to detect, or if the sample wasn’t collected properly. False positives, while rare, can result from the probe cross-reacting with related but harmless Neisseria species that naturally live in the throat or other body sites, contamination during processing, or even data entry errors.
DNA Probe vs. NAAT Testing
If your provider ordered a GC DNA probe, it’s worth understanding how it compares to the newer standard: nucleic acid amplification tests, or NAATs. NAATs work differently. Instead of simply detecting genetic material that’s already present, they make millions of copies of any target DNA in the sample first, then look for a match. This amplification step makes NAATs far more sensitive.
In head-to-head comparisons, NAATs detected 17 to 38% more chlamydia infections in women than the DNA probe did. For gonorrhea, modern NAAT platforms report sensitivity and specificity both at or near 100%. NAATs also work reliably with urine samples, which makes testing easier and less invasive. The CDC now recommends NAATs as the preferred method for gonorrhea and chlamydia screening, and most major labs have transitioned to them. If you see “GC/CT NAAT” or “Aptima” on your lab order, that’s the newer test.
The DNA probe is still used in some clinics and public health settings, particularly for confirming the identity of bacteria already grown in culture. In that role (culture confirmation rather than initial screening), it performs extremely well, with studies showing 100% sensitivity and 100% specificity across nearly 200 tested strains.
Understanding Your Results
A negative result means the bacteria was not detected in your sample at the time of collection. Keep in mind that if you were exposed very recently, the infection may not yet be detectable. A positive result means the target organism’s genetic material was found, confirming an active infection.
If you test positive for gonorrhea, treatment involves antibiotics. You should also notify recent sexual partners so they can get tested and treated. Retesting three months after completing treatment is recommended because reinfection is common. This follow-up test is important even if you took the full course of medication and your symptoms resolved.
Who Should Be Screened
CDC screening guidelines recommend routine gonorrhea testing for sexually active women under 25, and for women 25 and older who have risk factors like a new partner, multiple partners, or a partner with a known STI. Pregnant women under 25 (or older if at increased risk) should be tested during pregnancy, with repeat testing in the third trimester. Men who have sex with men should be screened at least annually at all sites of contact, including the throat and rectum, regardless of condom use, and every 3 to 6 months if at higher risk. People living with HIV should be screened at their first evaluation and at least annually after that.
For heterosexual men at low risk, there isn’t enough evidence to recommend routine screening, though testing is appropriate whenever symptoms are present or a partner has been diagnosed.